Kakar P, Watson T, Lip GYH. Drug evaluation: rivaroxaban, an oral, direct inhibitor of activated factor X. Curr Opin Investig Drugs. 2007;8:256–65.
CAS
PubMed
Google Scholar
Kubitza D, Becka M, Wensing G, et al. Safety, pharmacodynamics, and pharmacokinetics of BAY 59–7939 – an oral, direct factor Xa inhibitor – after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873–80.
CAS
CrossRef
Google Scholar
Gruber A, Marzec UM, Buetehorn U, Hanson S, Perzborn E. Potential of activated prothrombin complex concentrate and activated Factor vII to reverse the anticoagulant effects of rivaroxaban in primates. Blood (ASH Annual Meeting Abstracts). 2008;112:1307:abstract 3825.
Google Scholar
Perzborn E, Trabandt A, Selbach K, Tinel H. Prothrombin complex concentrate reverses the effects of high-dose rivaroxaban in rats. J Thromb Haemost. 2009;7:379:abstract pp-mo-183.
Google Scholar
Perzborn E, Roehrig S, Straub A, Kubitza D, Misselwitz F. The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor. Nat Rev Drug Discov. 2011;10:61–75.
CAS
CrossRef
Google Scholar
Eriksson BI, Borris LC, Dahl OE, et al; ODIXa-hip study investigators. Oral, direct factor Xa inhibition with BAY 59–7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4:121–8.
Google Scholar
Turpie AG, Fisher WD, Bauer KA, et al; ODIXa-knee study group. BAY 59–7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study. J Thromb Haemost. 2005;3:2479–86.
CAS
CrossRef
Google Scholar
Eriksson BI, Borris LC, Dahl OC, et al; ODIXa-hip study investigators. A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59–7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374–81.
CAS
CrossRef
Google Scholar
Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 study group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765–75.
CAS
CrossRef
Google Scholar
Kakkar AK, Brenner B, Dahl OE, et al; RECORD2 investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008;372:31–9.
CAS
CrossRef
Google Scholar
Lassen MR, Ageno W, Borris LC, et al; RECORD3 investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776–86.
CAS
CrossRef
Google Scholar
Turpie AG, Lassen MR, Davidson BL, et al; RECORD4 investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RecoRd4): a randomised trial. Lancet. 2009;9676:1673–80.
CAS
CrossRef
Google Scholar
Agnelli G, Gallus A, Goldhaber SZ, et al; ODIXa-DVT study investigators. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939): the ODIXa- DVT (oral direct factor Xa inhibitor BAY 59–7939 in patients with acute symptomatic deep-vein thrombosis) study. Circulation. 2007;116:180–7.
CAS
CrossRef
Google Scholar
Buller HR, Lensing AW, Prins MH, et al; EINSTEIN-DVT Dose-Ranging Study investigators. A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis. The EINSTEIN- DvT Dose-Ranging Study. Blood. 2008;112:2242–7.
CAS
CrossRef
Google Scholar
EINSTEIN investigators, Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510.
CrossRef
Google Scholar
The EINSTEIN-PE investigators. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–97.
CrossRef
Google Scholar
Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther. 2011;9:841–4.
CAS
CrossRef
Google Scholar
Patel MR, Mahaffey KW, Garg J, et al; ROCKET AF investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.
CAS
CrossRef
Google Scholar
Hori M, Matsumoto M, Tanahashi N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation. Circ J. 2012;76:2104–11.
CAS
CrossRef
Google Scholar
Mega JL, Braunwald E, Mohanavelu S, et al; ATLAS ACS-TIMI 46 study group. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet. 2009;374:29–38.
Google Scholar
Mega JL, Braunwald E, Wiviott SD, et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9–19.
Google Scholar
Cohen AT, Spiro TE, Büller HR, et al. Extended-duration rivaroxaban thromboprophylaxis in acutely ill medical patients: MAGELLAN study protocol. J Thromb Thrombolysis. 2011;31:407–16.
CAS
CrossRef
Google Scholar
Cohen AT, Spiro TE, Büller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368:513–23.
CAS
CrossRef
Google Scholar
Eriksson BI, Borris LC, Dahl OE, et al. Dose-escalation study of rivaroxaban (BAY 59–7939) – an oral, direct factor Xa inhibitor – for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Res. 2007;120:685–93.
CAS
CrossRef
Google Scholar
Fisher WD, Eriksson BI, Bauer KA, et al. Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. Thromb Haemost. 2007;97:931–7.
CAS
PubMed
Google Scholar
Shantsila E, Lip GY. Apixaban, an oral, direct inhibitor of activated factor Xa. Curr Opin Investig Drugs. 2008;9:1020–33.
CAS
PubMed
Google Scholar
Lassen MR, Davidson BL, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007;5:2368–75.
CAS
CrossRef
Google Scholar
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;36:594–604.
CrossRef
Google Scholar
Lassen MR, Raskob GE, Gallus A, et al; ADVANCE-2 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375:807–15.
CAS
CrossRef
Google Scholar
Lassen MR, Gallus A, Raskob GE, et al; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363:2487–98.
CAS
CrossRef
Google Scholar
Botticelli Investigators, Writing Committee, Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost. 2008;6:1313–8.
CrossRef
Google Scholar
Agnelli G, Büller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.
CAS
CrossRef
Google Scholar
Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368:699–708.
CAS
CrossRef
Google Scholar
Connolly SJ, Eikelboom J, Joyner C, et al; AVERROES steering committee and investigators. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–17.
Google Scholar
Granger CB, Alexander JH, McMurray JJ, et al; ARISTOTLE committees and investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.
Google Scholar
APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, et al. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009;119:2877–85.
CrossRef
Google Scholar
APPRAISE-2 Investigators, Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011;365:699–708.
CrossRef
Google Scholar
Goldhaber SZ, Leizorovicz A, Kakkar AK, et al; Adopt trial investigators. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365:2167–77.
CAS
CrossRef
Google Scholar
Levine MN, Gu C, Liebman HA, et al. A randomized phase II trial of apixaban for the prevention of thromboembolism in patients with metastatic cancer. J Thromb Haemost. 2012;10:807–14.
CAS
CrossRef
Google Scholar
Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6:1542–9.
CAS
PubMed
Google Scholar
Wolzt M, Samama MM, Kapiotis S, Ogata K, Mendell J, Kunitada S. Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux. Thromb Haemost. 2011;105:1080–90.
CAS
CrossRef
Google Scholar
Mendell J, Chen S, He L, Desai M, Parasrampuria D. The effect of rifampin on the pharmacokinetics (PK)and pharmacodynamics (PD) of edoxaban in healthy subjects. J Thromb Haemost. 2014;12(Suppl 1):Abstract COA26.
Google Scholar
Zahir H, Matsushima N, Halim AB, et al. Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. Thromb Haemost. 2012;108:166–75.
CAS
CrossRef
Google Scholar
Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, biotransformation, and mass balance of edoxaban, a selective, direct factor Xa inhibitor, in humans. Drug Metab Dispos. 2012;40:2250–5.
CAS
CrossRef
Google Scholar
Koretsune Y, Yamashita T, Yasaka M. Evaluation of edoxaban in patients with atrial fibrillation and severe renal impairment. Eur Heart J. 2013;34(Suppl 1):abstract P520.
CrossRef
Google Scholar
Mendell J, Shi M. Safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of edoxaban in healthy post-menopausal or surgically sterile females, and healthy elderly males. Eur Heart J. 2011;32(Suppl 1):abstract P2614.
Google Scholar
Daiichi Sankyo Europe GmbH. LIXIANA® European Summary of Product Characteristics 2015. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002629/human_med_001874.jsp&mid=WC0b01ac058001d124.
Perosphere, Inc. Effects of a double-blind, single dose of PER977 administered alone, and following a single dose of edoxaban (PER977-P1). (clinicaltrials.gov identifier NCT01826266). US National Institutes of Health, clinicaltrials.gov. Available at: www.clinicaltrials.gov. Accessed 20 Nov 2014.
Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;[Epub ahead of print]. DOI: 10.1056/NEJMc1411800.
CrossRef
PubMed
Google Scholar
Perosphere, Inc. Study of PER977 administered to subjects with steady state edoxaban dosing and re-anticoagulation with edoxaban (clinicaltrials.gov identifier NCT02207257). US National Institutes of Health, clinicaltrials.gov. Available at: www.clinicaltrials.gov. Accessed 21 Nov 2014.
U.S. FDA Approves Daiichi Sankyo’s Once-Daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism. Available at: www.daiichisankyo.com. Accessed 15 Jan 2015.
Daiichi Sankyo’s Once-Daily LIXIANA® (edoxaban) Approved in the EU for stroke prevention in nonvalvular atrial fibrillation and for the treatment and prevention of recurrent DVT and PE. Available at: www.daiichisankyo.com. Accessed 01 July 2015.
Fuji T, Fujita S, Tachibana S, Kawai Y. A dose-ranging study evaluating the oral factor Xa inhibitor edoxaban for the prevention of venous thromboembolism in patients undergoing total knee arthroplasty. J Thromb Haemost. 2010;8:2458–68.
CAS
CrossRef
Google Scholar
Raskob G, Cohen AT, Eriksson BI, et al. Oral direct factor Xa inhibition with edoxaban from thromboprophylaxis after elective total hip replacement. Thromb Haemost. 2010;104:642–9.
CAS
CrossRef
Google Scholar
Fuji T, Wang CJ, Fujita S, et al. Edoxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty: The stars E-3 trial. Pathophysiol Haemos Thromb. 2009–2010;37:131–158 OC297.
Google Scholar
Fujita S, Fuji T, Tachibana S, Nakamura M, Kawai Y. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Pathophysiol Haemos Thromb. 2009–2010;37:P366.
Google Scholar
Fuji T, Fujita S, Tachibana S, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial. Blood. 2010;116:Abstract 3320.
Google Scholar
Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633–41.
CAS
CrossRef
Google Scholar
Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF-TIMI 48). Am Heart J. 2010;160:635–41.
CAS
CrossRef
Google Scholar
Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.
CAS
CrossRef
Google Scholar
Raskob G, Büller H, Prins M, et al. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials. J Thromb Haemost. 2013;11:1287–94.
CAS
CrossRef
Google Scholar
Hokusai-VTE investigators, Büller H, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–15.
CrossRef
Google Scholar
Kuroda Y, Hirayama C, Hotoda H, Nishikawa Y, Nishiwaki A. Postmarketing safety experience with edoxaban in Japan for thromboprophylaxis following major orthopedic surgery. Vasc Health Risk Manag. 2013;9:593–8.
CrossRef
Google Scholar
Salazar DE, Mendell J, Kastrissios H, et al. Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost. 2012;107:925–36.
CAS
CrossRef
Google Scholar
Turpie AG, Bauer KA, Davidson BL, et al; EXPERT Study Group. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost. 2009;101:68–76.
Google Scholar
Connolly SJ, Eikelboom J, Dorian P, et al. Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa). Eur Heart J. 2013;34:1498–505.
CAS
CrossRef
Google Scholar
Eriksson BI, Dahl OE, Lassen MR, Ward DP, Rothlein R, Davis G, Turpie AGG. Partial factor IXa inhibition with TTP889 for prevention of venous thromboembolism: an exploratory study. J Thromb Haemost. 2008;6:457–63.
CAS
CrossRef
Google Scholar
Green Cross Corporation. A study to access safety, tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of orally administered GCC-4401C in healthy volunteers (clinicaltrials.gov identifier NCT01954238). US National Institutes of Health, clinicaltrials.gov. Available at: www.clinicaltrials.gov. Accessed 21 Nov 2014.
Portola Pharmaceuticals. Acute medically ill VTE prevention with extended duration Betrixaban Study (The APEX Study). (clinicaltrials.gov identifier NCT01583218). US National Institutes of Health, clinicaltrials.gov. Available at: www.clinicaltrials.gov. Accessed 20 Nov 2014.
Cohen AT, Harrington R, Goldhaber SZ, Hull R, Gibson CM, Hernandex AF, Kitt MM, Lorenz TJ. The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. Am Heart J. 2014;167:335–41.
CrossRef
Google Scholar
Eikelboom JW, Zelenkofske SL, Rusconi CP. Coagulation factor IXa as a target for treatment and prophylaxis of venous thromboembolism. Arterioscler Thromb Vasc Biol. 2010;30:382–7.
CAS
CrossRef
Google Scholar